Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuity Genome Restorer Phase 1 trial for treatment-refractory multisystem diseases in Africa
PACTR202509813688898Phase 1Not yet recruiting
- Sponsor
- SCVX
- Start
- Jan 2026
- Countries
- 11
01
Overview
Phase 1, open-label trial in Hematopathy, diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM) and 14 more, sponsored by SCVX. Primary endpoints: Restoration of genomic continuity resonance, Blood regeneration and 3 more. Planned start Jan 2026; status: not yet recruiting.
02
Conditions
Hematopathydiabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)Wound infection (WI)
Beyond the preview
Go deeper on PACTR202509813688898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509813688898.